Cognitive Impairment, Insulin-like Growth Factor 1
Conditions
Keywords
sarcopenia, mortality
Brief summary
Insulin-like growth factor 1 (IGF)-1 is an important neuromyotrophic hormone. Disregulation of this hormone has been reported to influence the genesis of cognitive impairment and dementia in the elderly patients. We analyzed the possible link between IGF-1 and risk of Sarcopenia and Mortality in a cohort of elder patients with cognitive impairment.
Interventions
PROCEDUREIGF-1 serum value
Evaluation of IGF-1 serum value at baseline, 24 and 48 months
Sponsors
University of Roma La Sapienza
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
65 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of cognitive impairment (MMSE \< 24) * Age \> 65 ys
Exclusion criteria
* Diagnosis of pancreatic disorders * Diagnosis of acromegaly * Diagnosis of GH-related disorders * Recent bone fractures or immobility before the enrollment (3 months) * Cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| IGF-1 reduction in patients with sarcopenia | baseline, 24 months, 48 months | IGF-1 reduction could be linked to sarcopenia in patients with cognitive impairment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| IGF-1 reduction and mortality in patients with cognitive impairment | baseline, 24 months, 48 months | IGF-1 could be an independent risk factor for mortality in patients with cognitive impairment |
Countries
Italy
Outcome results
None listed